Paraoxonase 3 (PON3) is a 354 amino acid secreted enzyme encoded by the PON3 gene on chromosome 7q21.3. It belongs to the paraoxonase family, which also includes PON1 and PON2. PON3 is the least characterized member of this family but has emerged as a protein of significant interest due to its association with high-density lipoprotein (HDL) particles and its potential neuroprotective properties. Unlike PON1 and PON2, PON3 has relatively low paraoxonase activity but possesses robust lactonase activity, hydrolyzing a variety of lactones and organophosphate metabolites. Its expression is primarily hepatic, with secretion into the plasma where it associates with HDL particles.
| Paraoxonase 3 (PON3) |
|---|
| Protein Name | Paraoxonase 3 |
| Gene | [PON3](/genes/pon3) |
| UniProt ID | Q15166 |
| PDB Structure | 5O0T, 7CVD |
| Molecular Weight | 39.6 kDa (354 amino acids) |
| Subcellular Localization | Plasma (HDL-associated), Secreted, Liver |
| Protein Family | Paraoxonase family |
| Chromosomal Location | 7q21.3 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Atherosclerosis](/diseases/atherosclerosis), [Metabolic Syndrome](/diseases/metabolic-syndrome) |
PON3 shares structural features with other paraoxonase family members:
- Signal Peptide: N-terminal 20 amino acid signal peptide directs secretion.
- Beta-Propeller Domain: Six-bladed beta-propeller fold creates the structural core of the protein.
- Calcium-Binding Sites: Two calcium ions are essential for structural stability and enzymatic activity.
- Active Site: Hydrophobic pocket containing the active site for substrate binding.
- HDL-Binding Region: PON3 contains specific regions that facilitate association with HDL particles.
- Lactone-Binding Pocket: Differs from PON1 in substrate specificity, with preference for lactone substrates.
- Disulfide Bridges: Four conserved disulfide bonds stabilize the protein structure.
- N-glycosylation: Contains N-linked glycosylation sites important for secretion and stability.
- Free Thiol: Cys-284 is a free thiol important for antioxidant activity.
PON3 exhibits several enzymatic activities:
-
Lactonase Activity: Primary activity - hydrolyzes various lactones including homocysteine thiolactone, an atherogenic and neurotoxic compound[^2].
-
Organophosphate Hydrolysis: Lower paraoxonase activity compared to PON1, but can hydrolyze some organophosphates.
-
Antioxidant Activity: Protects LDL and HDL from oxidative modification through multiple mechanisms.
- HDL Particle Binding: PON3 associates with HDL through interactions with apolipoproteins, particularly apoA-I.
- Antioxidant Shield: Contributes to HDL's overall antioxidant capacity, protecting against lipid peroxidation.
- Cholesterol Efflux: May participate in reverse cholesterol transport.
- Primary Expression: Liver (hepatocytes) - main source of circulating PON3.
- Low Expression: Kidney, intestine, and other tissues express lower levels.
- Plasma: Circulates bound to HDL particles.
PON3 has been implicated in AD pathogenesis through multiple mechanisms:
- Oxidative Stress Reduction: The antioxidant activity of PON3 may protect against oxidative damage in AD brain[^3].
- Homocysteine Metabolism: Lactonase activity can hydrolyze neurotoxic homocysteine thiolactone.
- Lipid Metabolism: HDL-associated PON3 may affect brain lipid homeostasis.
- Expression Changes: Altered PON3 expression reported in AD brain and CSF.
- Aβ Protection: Preliminary evidence suggests PON3 may protect against amyloid-β toxicity.
- Oxidative Stress: PD involves significant oxidative stress; PON3 antioxidant function may be protective.
- Neuroinflammation: May modulate neuroinflammatory responses.
- Lipid Homeostasis: Dopaminergic neurons are rich in lipids; PON3 may protect neuronal membranes.
- ALS: Altered PON3 expression in some ALS studies.
- Multiple Sclerosis: May be affected in demyelinating diseases.
- Stroke: Antioxidant function may protect against ischemic damage.
- Enzyme Enhancement: Therapies that increase PON3 expression or activity.
- HDL-Targeted Therapies: HDL-raising therapies may increase PON3 availability.
- Lactonase Boosters: Small molecules that enhance lactonase activity.
- Gene Therapy: Experimental approaches to increase PON3 expression.
- PON3 Agonists: Currently limited but under investigation.
- HDL Modulators: Statins and other HDL-modifying drugs may indirectly affect PON3.
- Antioxidant Combinations: PON3-based combination therapies.
¶ GWAS and Association Studies
- Cardiovascular Disease: PON3 variants associated with HDL levels and cardiovascular risk.
- Neurodegeneration: Less well-studied than PON1 in neurodegenerative disease genetics.
- Metabolic Traits: Some association with lipid traits and diabetes.
- Transcriptional Control: Regulated by statins, fibrates, and inflammatory signals.
- Age-Related Changes: Declines with age, which may contribute to age-related neurodegeneration.
- Lifestyle Factors: Exercise and diet can modulate PON3 expression.
- Blood Biomarker: PON3 activity in plasma being investigated as a peripheral biomarker.
- Disease Severity: Correlates with disease severity in some studies.
- Therapeutic Monitoring: May serve as a marker of therapeutic response.